JP2024539126A5 - - Google Patents

Info

Publication number
JP2024539126A5
JP2024539126A5 JP2024523582A JP2024523582A JP2024539126A5 JP 2024539126 A5 JP2024539126 A5 JP 2024539126A5 JP 2024523582 A JP2024523582 A JP 2024523582A JP 2024523582 A JP2024523582 A JP 2024523582A JP 2024539126 A5 JP2024539126 A5 JP 2024539126A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
polynucleotide
polynucleotide according
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539126A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078331 external-priority patent/WO2023069969A1/en
Publication of JP2024539126A publication Critical patent/JP2024539126A/ja
Publication of JP2024539126A5 publication Critical patent/JP2024539126A5/ja
Pending legal-status Critical Current

Links

JP2024523582A 2021-10-20 2022-10-19 最適なシグナル伝達を有するcar構築物によるnk細胞の操作 Pending JP2024539126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257608P 2021-10-20 2021-10-20
US63/257,608 2021-10-20
PCT/US2022/078331 WO2023069969A1 (en) 2021-10-20 2022-10-19 Engineering nk cells with a car construct with optimal signaling

Publications (2)

Publication Number Publication Date
JP2024539126A JP2024539126A (ja) 2024-10-28
JP2024539126A5 true JP2024539126A5 (cg-RX-API-DMAC7.html) 2025-10-15

Family

ID=86058649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523582A Pending JP2024539126A (ja) 2021-10-20 2022-10-19 最適なシグナル伝達を有するcar構築物によるnk細胞の操作

Country Status (12)

Country Link
US (1) US20240408203A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419128A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539126A (cg-RX-API-DMAC7.html)
KR (1) KR20240099309A (cg-RX-API-DMAC7.html)
CN (1) CN118265535A (cg-RX-API-DMAC7.html)
AR (1) AR127405A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022369294A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233096A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024002936A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024004772A (cg-RX-API-DMAC7.html)
TW (1) TW202330586A (cg-RX-API-DMAC7.html)
WO (1) WO2023069969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121337979A (zh) * 2025-04-03 2026-01-16 上海恩凯细胞技术有限公司 新型嵌合抗原受体修饰的免疫细胞及其在制备药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110475857B (zh) * 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
US11541076B2 (en) * 2017-01-13 2023-01-03 Celdara Medical, Llc Chimeric antigen receptors targeting TIM-1
CN107573419A (zh) * 2017-01-24 2018-01-12 深圳市体内生物医药科技有限公司 一种增强t细胞抗肿瘤活性的核酸分子
EP3668899A4 (en) * 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
JP2022548902A (ja) * 2019-09-18 2022-11-22 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法
US20240189357A1 (en) * 2021-04-14 2024-06-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors to target cd5-positive cancers
EP4332118A1 (en) * 2021-04-29 2024-03-06 Korea Research Institute of Bioscience and Biotechnology Novel anti-cd5 chimeric antigen receptor and immune cell expressing same
CA3221568A1 (en) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Chimeric antigen receptor to target hla-g-positive cancers
JP2024525609A (ja) * 2021-07-09 2024-07-12 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Trop-2陽性癌を標的とするキメラ抗原受容体

Similar Documents

Publication Publication Date Title
US20240041933A1 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
Bontkes et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells
JP2024138280A5 (cg-RX-API-DMAC7.html)
JP7334985B2 (ja) 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
JP2023036712A (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
JP2024527559A5 (cg-RX-API-DMAC7.html)
JP2021525534A5 (cg-RX-API-DMAC7.html)
BR112019022356A2 (pt) Reagentes de partícula oligoméricos e métodos de uso dos mesmos
JP2024514203A5 (cg-RX-API-DMAC7.html)
JP2024521185A5 (cg-RX-API-DMAC7.html)
AU2016306209A1 (en) Bispecific CAR T-cells for solid tumor targeting
JP2017525364A (ja) 免疫細胞を惹起及び/又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞
US12280092B2 (en) Reprogrammed T cell-like NK cells
CN106535925A (zh) 基于car的免疫治疗
JP2024525609A5 (cg-RX-API-DMAC7.html)
JP2022548902A5 (cg-RX-API-DMAC7.html)
CN111918964A (zh) 促进免疫细胞增殖的方法
CN114599784A (zh) 具有cd45ra+和ccr7+的细胞表面标志物的t细胞的制备方法
JP2022513099A5 (cg-RX-API-DMAC7.html)
Weinstein-Marom et al. Combined expression of genetic adjuvants via mRNA electroporation exerts multiple immunostimulatory effects on antitumor T cells
EP4476246A2 (en) Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
JP6684211B2 (ja) B細胞集団の製造方法
US20250073268A1 (en) Chimeric cd40 polypeptides and methods of use in immunotherapy
RU2024113197A (ru) Модифицирование nk-клеток конструкцией car с оптимальной передачей сигнала
WO2025166113A1 (en) Cell-free implants for in vivo recruitment, activation, and reprogramming of immune cells